KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vertex Pharmaceuticals (VRTX) Capital Expenditures: 2009-2025

Historic Capital Expenditures for Vertex Pharmaceuticals (VRTX) over the last 17 years, with Sep 2025 value amounting to $101.8 million.

  • Vertex Pharmaceuticals' Capital Expenditures rose 50.37% to $101.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $380.8 million, marking a year-over-year increase of 44.68%. This contributed to the annual value of $297.7 million for FY2024, which is 48.55% up from last year.
  • Latest data reveals that Vertex Pharmaceuticals reported Capital Expenditures of $101.8 million as of Q3 2025, which was down 30.13% from $145.7 million recorded in Q2 2025.
  • Over the past 5 years, Vertex Pharmaceuticals' Capital Expenditures peaked at $145.7 million during Q2 2025, and registered a low of $33.6 million during Q4 2022.
  • Its 3-year average for Capital Expenditures is $71.5 million, with a median of $67.7 million in 2024.
  • Examining YoY changes over the last 5 years, Vertex Pharmaceuticals' Capital Expenditures showed a top increase of 264.52% in 2021 and a maximum decrease of 70.02% in 2021.
  • Vertex Pharmaceuticals' Capital Expenditures (Quarterly) stood at $61.8 million in 2021, then crashed by 45.63% to $33.6 million in 2022, then surged by 72.92% to $58.1 million in 2023, then skyrocketed by 59.38% to $92.6 million in 2024, then spiked by 50.37% to $101.8 million in 2025.
  • Its last three reported values are $101.8 million in Q3 2025, $145.7 million for Q2 2025, and $40.7 million during Q1 2025.